文献速递心血管胸部CT

他汀类药物对HIV感染者冠状动脉周围脂肪组织密度的影响:来自REPRIEVE试验的见解

Statin Effects on Pericoronary Adipose Tissue Density in People With HIV: Insights From the REPRIEVE Trial.
PubMed 文献 · JACC Cardiovasc Imaging · 2025-12-01

REPRIEVE机制CT亚组(n=753)显示,HIV感染者基线冠状动脉周围脂肪组织(PCAT)密度为-87.7±10.5 HU,2年内平均增加4.5 HU(95%CI 3.8-5.2,P<0.001);匹伐他汀可阻止冠状动脉疾病负荷高(节段受累评分≥4)者的这一增加(-1.7 HU vs +3.8 HU,P=0.016)。基线PCAT密度与全因死亡独立相关(每+10 HU,HR 1.95,95%CI 1.03-3.69,P=0.040),但与MACE无显著关联。

要点

  • HIV感染者PCAT密度2年内平均增加4.5 HU(95%CI 3.8-5.2,P<0.001)。
  • 节段受累评分≥4者中,匹伐他汀组PCAT密度变化-1.7 HU vs 安慰剂组+3.8 HU(P=0.016)。
  • 基线PCAT密度每增加10 HU,全因死亡HR 1.95(95%CI 1.03-3.69,P=0.040)。

核心结论

  • HIV感染者PCAT密度随时间增加,匹伐他汀可减轻高冠状动脉疾病负荷者的这一增加;PCAT密度与易损斑块形态及全因死亡相关,支持其作为HIV感染者的预后影像生物标志物。

研究设计与样本

  • REPRIEVE随机试验机制CT亚组,n=753,平均年龄51±6岁,女性17%;基线及2年非增强CT测PCAT密度,对比增强CT血管造影评估斑块体积;按节段受累评分0、1-3、≥4分层,并校正技术参数、动脉粥样硬化性心血管疾病风险、体重指数、炎症生物标志物及他汀分组。

关键影像表现/征象

  • 基线PCAT密度为-87.7±10.5 HU,2年内增加4.5 HU(95%CI 3.8-5.2,P<0.001)。
  • 节段受累评分≥4者中,匹伐他汀组PCAT密度变化-1.7 HU vs 安慰剂组+3.8 HU(P=0.016)。
  • PCAT密度每增加10 HU,非钙化斑块体积增加5.0 mm3(P=0.075),钙化斑块进展减少3.2 mm3(P=0.031)。

诊断标准与关键数值

  • 基线PCAT密度与全因死亡独立相关:每+10 HU,HR 1.95(95%CI 1.03-3.69,P=0.040),与MACE无显著关联。
  • 中位随访6.3年,4.2%患者死亡。

临床应用与阅片要点

  • 非增强CT可测量PCAT密度,用于HIV感染者心血管风险分层。
  • 节段受累评分≥4者PCAT密度变化可能反映他汀疗效。
  • PCAT密度升高可能与易损斑块形态及全因死亡风险相关,可结合斑块体积变化解读。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: The effects of statin therapy on pericoronary adipose tissue (PCAT) and its relationship with plaque progression and outcomes in people with HIV (PWH) remain poorly understood.

OBJECTIVES: The aim of this study was to evaluate PCAT density changes over time; statin effects on PCAT; and associations among PCAT changes, coronary plaque, and clinical outcomes.

METHODS: In the REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) mechanistic computed tomographic (CT) substudy (n = 753, mean age: 51 ± 6 years, 17% women), PCAT density was measured from noncontrast CT images at baseline and 2 years, while coronary plaque volumes (total, calcified, and noncalcified) were assessed from contrast-enhanced CT angiograms. Analyses were stratified by coronary artery disease burden (segment involvement score 0, 1-3, or ≥4) and adjusted for technical parameters, atherosclerotic cardiovascular disease risk, body mass index, inflammatory biomarkers, and statin allocation. Associations among PCAT, plaque changes, and events (all-cause mortality, major adverse cardiovascular events [MACE], and MACE or death) were evaluated.

RESULTS: Baseline PCAT density was -87.7 ± 10.5 HU, increasing by 4.5 HU (95% CI: 3.8-5.2; P < 0.001) over 2 years. Pitavastatin prevented this increase in participants with segment involvement scores ≥4 (-1.7 HU vs +3.8 HU; P = 0.016, pitavastatin vs placebo, respectively). Greater PCAT density was associated with higher noncalcified plaque volume (per +10 HU, +5.0 mm3; P = 0.075) and reduced calcified plaque progression (-3.2 mm3; P = 0.031). Over a median of 6.3 years, 4.2% of patients died. Baseline PCAT density was independently associated with all-cause mortality (HR per +10 HU: 1.95; 95% CI: 1.03-3.69; P = 0.040), but not MACE.

CONCLUSIONS: PCAT density increases over time in PWH, but pitavastatin mitigates this in those with high coronary artery disease burden. PCAT density is associated with vulnerable plaque morphology and all-cause mortality, supporting its potential as a prognostic imaging biomarker in PWH. (Randomized Trial to Prevent Vascular Events in HIV [REPRIEVE]; NCT02344290).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Foldyna B, Hadzic I, Mayrhofer T, et al. Statin Effects on Pericoronary Adipose Tissue Density in People With HIV: Insights From the REPRIEVE Trial. JACC Cardiovasc Imaging. 2025. PMID: 41324519. doi:10.1016/j.jcmg.2025.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。